Rocket Pharmaceuticals Reports Officer and Director Changes
Ticker: RCKTW · Form: 8-K · Filed: Aug 25, 2025 · CIK: 1281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKTW) |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, officer-appointment, director-election
TL;DR
Rocket Pharma's board and exec team got a shake-up, effective Aug 20.
AI Summary
Rocket Pharmaceuticals, Inc. filed an 8-K on August 25, 2025, reporting changes effective August 20, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the compensatory arrangements are not provided in this excerpt.
Why It Matters
Changes in a company's leadership and executive compensation can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially without immediate detailed explanations, can introduce uncertainty about the company's direction and stability.
Key Players & Entities
- Rocket Pharmaceuticals, Inc. (company) — Registrant
- August 20, 2025 (date) — Effective date of reported changes
- August 25, 2025 (date) — Filing date of the 8-K
FAQ
What specific changes were made regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, but the specific individuals and their roles are not detailed in this excerpt.
What is the effective date of these reported changes?
The earliest event reported, which is the effective date of the changes, is August 20, 2025.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed as of August 25, 2025.
What are the main topics covered in this 8-K filing?
This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is Rocket Pharmaceuticals, Inc.'s state of incorporation and principal executive office address?
Rocket Pharmaceuticals, Inc. is incorporated in Delaware and its principal executive offices are located at 9 Cedarbrook Drive, Cranbury, NJ 08512.
Filing Stats: 626 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2025-08-25 16:05:53
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
Filing Documents
- ef20054457_8k.htm (8-K) — 27KB
- 0001140361-25-032502.txt ( ) — 150KB
- rckt-20250820.xsd (EX-101.SCH) — 4KB
- rckt-20250820_lab.xml (EX-101.LAB) — 21KB
- rckt-20250820_pre.xml (EX-101.PRE) — 16KB
- ef20054457_8k_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. On August 20, 2025, Aaron Ondrey resigned as Chief Financial Officer of Rocket Pharmaceuticals, Inc. (the "Company"), effective September 5, 2025, to pursue other opportunities. On August 25, 2025, Martin Wilson, the Company's General Counsel and Chief Corporate Officer and the Company's Corporate Secretary, was appointed as the Company's interim Principal Financial Officer, effective September 8, 2025. Mr. Wilson, age 48, joined the Company as General Counsel and Chief Compliance Officer in November 2021 and became Chief Corporate Officer in March 2024. Mr. Wilson has nearly 20 years of legal, compliance and executive experience and accomplishment within the life sciences industry. Before joining the Company, Mr. Wilson was General Counsel and Chief Corporate Officer at Ichnos Sciences Inc. ("Ichnos"), a research and development company focused on oncology, autoimmune disease and pain management, from January 2020 through November 2021. Prior to his time at Ichnos, Mr. Wilson served as General Counsel at Teligent Inc., a generic pharmaceutical company, from April 2017 through December 2019. Mr. Wilson earned his Juris Doctorate from Villanova University Charles Widger School of Law. There is no family relationship between Mr. Wilson and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer. In addition, there are no transactions between the Company and Mr. Wilson, or any member of Mr. Wilson's immediate family, of the type set forth in Item 404(a) of Regulation S-K, other than the compensation received by Mr. Wilson for his current positions with the Company.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: August 25, 2025 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP